Highly Potent Active Pharmaceutical Ingredients 2022 Conference

HPAPI containment and facility design for successful exposure control

Conference Proceedings

Standard Price

US$ 616.05

Change your currency: USD EUR GBP

User Details

For the latest COVID-19 Travel restrictions and recommendations please click here

The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs, along with the increase in associated toxicities, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. The conference will encompass the critical topics including risk assessment, occupational toxicology, engineering controls for containment, facility design, and the impact of pharmaceutical manufacture on the environment.

This two-day agenda offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading pharmaceutical and biotechnology companies.

Benefits of Attending

  • Dissect comprehensive hazard assessment and occupational exposure limit determination
  • Evaluate the increasing trend toward more potent therapies and the consequences of the changing face of pharma
  • Assess engineering containment controls, from isolators and barriers to fully automated lines
  • Explore the employment of cleaning validation, organisational controls, and facility as key measure to tackle cross contamination

Who should attend

Key job titles include:
  • Head of Occupational hygiene
  • Head of Industrial hygiene
  • Head of Containment
  • Head of Corporate Toxicology
  • Head of Validation
  • Director of Operation Quality
  • Director of EHS
  • Director of Drug Safety Evaluation
  • Industrial Engineer
  • Validation Expert
  • Manufacturing Specialist
  • QA Specialist/Manager
  • Scale-up Operations Manager


  • Adela Maghear, President, Institut Vert
  • Anna Kulesza, Director Pharmaceutical Development, Clovis Oncology
  • Christophe Dehondt, Global Head of EHS and BCM, Novartis, Advanced Accelerator Applications
  • Damien Boyd, EHS Specialist Occupational Hygiene, GlaxoSmithKline
  • David Eherts, Principal Consultant, National Safety Council - ORCHSE (Eherts Consulting LLC)
  • Ester Lovsin Barle, Head of Product Stewardship and Health , Takeda Pharmaceutical Company Limited
  • Fabio Zenobi, Director, BSP Pharmaceuticals S.p.A.
  • Justin Mason-Home, Owner, Director, HPAPI Project Services Limited
  • Martin Kohan, Senior Occupational Toxicologist, AstraZeneca
  • Michael Perry, Director, Pharmadagio Limited
  • Olindo Lazzaro, Head, Global Occupational Safety, Novartis
  • Reinhold Maeck, Head of Corporation EH&S Regulatory Intelligence, Boehringer Ingelheim
  • Richard Denk, Senior Consultant Aseptic Processing & Containment, SKAN AG
  • Robert Sussman, Managing Director, Trinity Consultants - SafeBridge┬« Regulatory & Life Sciences Group
  • Thomas Adam, QA-Manager, Bayer AG, R&D, Pharmaceutical
  • Toral Mehta, SME, Industrial Hygiene, Global EHS, MSD Animal Health
  • Ulrich Rumenapp, Head of Launch Preparation and Coordination, Bayer AG

Please fill in your name and email to receive the Conference Agenda of this event.


Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK

Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Physical Event
Reference :ASDE-23469